There are high number of clear evidence that breastfeeding provides best nutrition that you can give to your baby. It is also evident that lactation is good for mothers health as well. Evolution has designed breastfeeding in a way that it caters all nutritional need of your child. However modern medicine is quite new for evolution, that is why mothers body is not well prepared to filter unnecessary chemical found in medicines. It becomes a necessity to figure out which drug is safe and which drug is dangerous for your newborn while nursing. In this article we will understand function of Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule and its suitability with breastfeeding.
What is Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule used for?
Nitrofurantoin monohydrate/macrocrystals capsules are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin monohydrate/macrocrystals capsules and other antibacterial drugs, nitrofurantoin monohydrate/macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin monohydrate/macrocrystals capsules are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES.) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin monohydrate/macrocrystals capsules, other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin monohydrate/macrocrystals capsules, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized.
Is using Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule safe or dangerous while breastfeeding?
Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule is primarily made of two things Nitrofurantoin, Nitrofurantoin. What we have done here is we have analyzed Nitrofurantoin for its impact on breastfeeding and analyzed Nitrofurantoin for its impact on breastfeeding. Our analysis of Nitrofurantoin and Nitrofurantoin suggests that Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule is probably safe in breastfeeding however we suggest you to check detail about both below.
Statement of Manufacturer/Labeler about breastfeeding usage
Nursing Mothers Nitrofurantoin has been detected in human breast milk in trace amounts. Because of the potential for serious adverse reactions from nitrofurantoin in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See CONTRAINDICATIONS .)
Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule Breastfeeding Analsys
SafeCAS Number: 67-20-9
Excretion into breast milk is clinically non-significant with no side-effects observed among breastfed infants from treated mothers except rare cases of diarrhea. Do not use while the infant is younger of two weeks of age or suffers of G-6-P dehydrogenase deficiency to avoid likelihood of hemolysis. Be aware of false negative results that may be obtained from febrile infants with bacterial cultures when the mother is on antibiotics. Also, the possibility of developing diarrhea due to bacterial flora imbalance.
SafeCAS Number: 67-20-9
Excretion into breast milk is clinically non-significant with no side-effects observed among breastfed infants from treated mothers except rare cases of diarrhea. Do not use while the infant is younger of two weeks of age or suffers of G-6-P dehydrogenase deficiency to avoid likelihood of hemolysis. Be aware of false negative results that may be obtained from febrile infants with bacterial cultures when the mother is on antibiotics. Also, the possibility of developing diarrhea due to bacterial flora imbalance.
Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule Breastfeeding Analsys - 2
CAS Number: 67-20-9
Administration of nitrofurantoin directly to infants under 1 month of age and in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency is contraindicated because of potential hemolysis in these infants. However, the time of greatest risk for hemolysis in fullterm newborns without G6PD deficiency might be as short as 8 days after birth.[1] Nitrofurantoin doses in milk are low and it can be used while breastfeeding older infants, but alternate drugs are preferred in mothers of infants under 8 days of age, or infants with G6PD deficiency of any age. Observe infants for possible diarrhea.
CAS Number: 67-20-9
Administration of nitrofurantoin directly to infants under 1 month of age and in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency is contraindicated because of potential hemolysis in these infants. However, the time of greatest risk for hemolysis in fullterm newborns without G6PD deficiency might be as short as 8 days after birth.[1] Nitrofurantoin doses in milk are low and it can be used while breastfeeding older infants, but alternate drugs are preferred in mothers of infants under 8 days of age, or infants with G6PD deficiency of any age. Observe infants for possible diarrhea.
What should I do if I am breastfeeding mother and I am already exposed to Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule?
It is always a good idea to keep your healthcare provider or doctor informed about your drug usage during pregnancy and breastfeeding but if you have not informed your doctor about Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule and have used it then do not panic as Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule is mostly safe in breastfeeding and should not cause any harm to your baby.
My doctor has prescribed me Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule, what should I do?
Usage of Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule is safe for nursing mothers and baby, No worries.
If I am using Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule, will my baby need extra monitoring?
No
Who can I talk to if I have questions about usage of Nitrofurantoin Monohydrate/ Macrocrystalline | Nitrofurantoin Capsule in breastfeeding?
US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week